One of the cases in the Edenfield et al. study had a PD-L1 expression of 1%, MSS, a low TMB, and no actionable mutations in metastatic ACC, receiving durvalumab with tremelimumab, and had a sustained complete response at 18 months [27]. The gene discussed is CD274; the disease is adrenal cortex carcinoma.